GSK plc entered into an agreement to acquire Aiolos Bio, Inc., a clinical-stage biopharmaceutical company focused on treatments for certain respiratory and inflammatory conditions, for a $1 billion upfront and as much as $400 million in success-based regulatory milestones.   The acquisition provides GSK with access to Aiolos’ AIO-001, a potential best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II development for the treatment of asth...